Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 647 across all filing types
Latest filing 2026-05-22 Capital/Financing Update
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 80% confidence The document is a Major Information Report (주요사항보고서) filed to the Korean Financial Services Commission and Korea Exchange detailing the decision to issue private placement convertible bonds, including terms, conversion, early redemption, use of proceeds, and investor details. This is not an annual or interim financial statement, nor a simple publication announcement or officer certification. It is a financing update concerning capital structure and fundraising activities. Therefore, it best fits the Capital/Financing Update category (CAP).
2026-05-22 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 93% confidence The document is a Korean "주요사항보고서(유상증자결정)" (Material Fact Report on Paid-in Capital Increase Decision), detailing the terms of a third-party allotment, issuance price, number of shares, subscription and listing dates, use of proceeds, and allottee information. This is a clear announcement of a share issuance/capital change, matching the Share Issue/Capital Change (SHA) category rather than a full report type or a simple publication notice.
2026-05-22 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Capital/Financing Update Classification · 85% confidence The document is a regulatory disclosure detailing a stock collateral (share pledge) agreement by the largest shareholder to secure a new borrowing, including amended contract terms, debt amounts, and collateral details. This is not a management change, earnings release, or annual report, but rather an update on the company’s financing activity (share-backed loan). Therefore it best fits the Capital/Financing Update category.
2026-05-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a detailed “주식등의 대량보유상황보고서” (Report on Large Holdings of Shares) under Korea’s Capital Markets Act, showing shareholding numbers, percentages, related party schedules, changes in holdings, and collateral arrangements. This is a regulatory disclosure of significant share ownership and changes, matching the Major Shareholding Notification category (MRQ).
2026-05-21 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Capital/Financing Update Classification · 80% confidence The document is a Korean stock exchange disclosure (정정신고) detailing the correction of a previously announced stock collateral (pledge) contract by the company’s major shareholder, including loan amounts, collateral details, and contract dates. This is an announcement of a financing arrangement (collateral for borrowings), not an earnings report, share issuance, or management change. It therefore falls under Capital/Financing Update (CAP).
2026-05-19 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (Korean for Quarterly Report) covering the period January 1, 2026 to March 31, 2026 (1st quarter of fiscal year 29). It contains detailed operational and financial data, business overview, segment performance, and full tabulated figures—characteristics of a comprehensive interim/quarterly financial report rather than a short announcement or press release. Therefore, it should be classified as an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.